Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04573959 · ClinicalTrials.gov registry record · NA

Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System

A NA study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Capso Vision.

Completed
Registry status
NA
Development phase
84
Enrollment target
1
Study location

NCT04573959 is a NA study of Crohn Disease and Inflammatory Bowel Diseases that has completed, run by Capso Vision. The registered enrollment target is 84 participants, below the 204-participant average among 71 other Crohn Disease trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04573959, a NA study of Crohn Disease and Inflammatory Bowel Diseases, has completed, sponsored by Capso Vision.

COMPLETED
Registry status
NA
Development phase
84 participants
Enrollment target
1
Study location

Study Summary

To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam® SV-2 and SV-3 capsule endoscopy systems.

Interventions

  • DEVICE SV-3 Capsule Endoscopy

Study Locations (1)

California

  • CapsoVision, Inc. - Saratoga

Trial Details

FieldValue
Enrollment Target 84 participants
Start Date 2015-10-01
Est. Completion 2020-06-11
Phase NA

Sponsor

Capso Vision

6 total trials

What the Registry Record Tells You About NCT04573959

The ClinicalTrials.gov registry entry for NCT04573959 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 71 other Crohn Disease trials with a reported enrollment target (59% lower). The listed sponsor is Capso Vision, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which SV-3 Capsule Endoscopy is the first listed.

NCT04573959 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04573959 about?

NCT04573959 is a clinical study titled "Validation of CapsoVision CapsoCam® SV-3 Capsule Endoscopy System". To validate an updated version of CapsoCam® SV-3 Endoscopy System brand name CapsoCam Plus™) with respect to the reproducibility of the system to capture and download small bowel images in a manner consistent with the predicate CapsoCam® SV-2 and SV-3 capsule endoscopy systems.

What is the current status of trial NCT04573959?

This trial is currently completed. It is a NA study. The enrollment target is 84 participants. The study started on 2015-10-01. Estimated completion is 2020-06-11.

What conditions does trial NCT04573959 study?

This clinical trial studies the following conditions: Crohn Disease, Inflammatory Bowel Diseases, Celiac Disease, Ulcer, Intestinal Disease.

What interventions are being tested in trial NCT04573959?

The interventions under investigation include: SV-3 Capsule Endoscopy (DEVICE).

Who is sponsoring clinical trial NCT04573959?

This trial is sponsored by Capso Vision, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04573959 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.